In wide-ranging amicus briefs, experts again urge the Fifth Circuit to reject restrictions on telehealth access to mifepristone

ChaseSeptember 10, 2026

Ahead of oral argument in Louisiana v. U.S. Food and Drug Administration (FDA) on September 9, a wide range of experts — including the American College of Obstetricians and Gynecologists, American College of Emergency Physicians, the National Domestic Violence Hotline, the Disability Rights Education & Defense Fund, the NAACP Legal Defense & Educational Fund, pharmaceutical and biotech manufacturers, and former military officials — are urging the U.S. Court of Appeals for the Fifth Circuit to reject anti-abortion politicians’ effort to end telemedicine and mail and pharmacy access to mifepristone nationwide.Mifepristone is used in nearly two-thirds of U.S. abortions, with more than 1 in 4 patients

Abortion Pills Abortion Rights ACLU Healthcare Reproductive rights Telehealth United States

By Chase